Novavax Inc. (NVAX)
7.92
-0.10 (-1.25%)
At close: Feb 20, 2025, 3:59 PM
7.93
0.13%
After-hours: Feb 20, 2025, 06:41 PM EST
undefined% (undefined)
| Bid | 7.92 |
| Market Cap | 1.27B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | -3.63 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.93 |
| Volume | 2,532,376 |
| Avg. Volume (20D) | 3,879,464 |
| Open | 8.06 |
| Previous Close | 8.02 |
| Day's Range | 7.70 - 8.14 |
| 52-Week Range | 3.81 - 23.86 |
| Beta | undefined |
About NVAX
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical tria...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 5, 1995
Employees 1,543
Stock Exchange NASDAQ
Ticker Symbol NVAX
Website https://www.novavax.com
Analyst Forecast
According to 6 analyst ratings, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $18.5, which is an increase of 133.59% from the latest price.
Buy 50.00%
Hold 33.33%
Sell 16.67%
Next Earnings Release
Novavax Inc. is scheduled to release its earnings on Feb 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+0.12%
Shares of vaccine stocks are trading lower after t...
Unlock content with
Pro Subscription
3 weeks ago
+2.15%
Shares of vaccine stocks are trading higher. HHS Secretary nominee Robert F. Kennedy Jr. reportedly said he is not anti-vaccine ahead of upcoming confirmation hearings.
